Janux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash Value

2026-05-04 19:33:55 ET

Background

Janux Therapeutics, Inc. ( JANX ) is a biopharmaceutical company in clinical stage, focused on the development of immunotherapies against various types of cancer and more recently autoimmune diseases. In my last analysis , published on 31st July 2025, I provided the stock with a Buy rating, supported by two main pillars: 1) the large cash position, over $1 billion in cash & equivalents by the end of Q1 2025. 2) low quarterly cash burnout rate: I estimated the average burn rate in 2025 to be around $40 million. 2) Pipeline potential, mainly based on the Tumor Activated Immunomodulator (TRACIr) and the Adaptative immune Response Modulator ((ARM)) platforms. While also highlighting the lack of near-term catalysts, which were likely to expose investors to large share price fluctuations due to sector headwinds and/or potential negative clinical outcomes given the early stage pipeline....

Read the full article on Seeking Alpha

For further details see: